证券代码：688799 证券简称：华纳药厂 公告编号：2025-077 湖南华纳大药厂股份有限公司 持股 5%以上股东、董事之一致行动人减持股份结 果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东、董事及其一致行动人持股的基本情况 本次减持计划实施前，湖南华纳大药厂股份有限公司（以下简称"公司"） 股东、董事徐燕先生直接持有公司股份 18,480,000 股（占公司总股本 14.0725%）， 其一致行动人徐小强先生直接持有公司股份 1,970,920 股（占公司总股本 1.5009%）。上述股份来源于公司首次公开发行前持有的股份及公司实施资本公积 金转增股本新增的无限售条件流通股，首次公开发行前持有的股份已于 2022 年 7 月 13 日起上市流通。 减持计划的实施结果情况 公司于 2025 年 7 月 28 日披露了《湖南华纳大药厂股份有限公司持股 5%以 上股东、董事之一致行动人减持股份计划公告》（公告编号：2025-067），公司股 东徐小强先生基于自身资金需求，计划减持公 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced the completion of a share reduction plan by major shareholder Xu Yan and his associate Xu Xiaoqiang, who collectively reduced their holdings by 1.2961 million shares, representing 0.9870% of the company's total share capital [1] Group 1 - The share reduction occurred between September 1, 2025, and September 12, 2025 [1] - The reduction plan has been fully implemented [1]

Core Points - Warner Pharmaceuticals announced that shareholder Xu Xiaoqiang reduced his holdings by 1.2961 million shares, representing 0.9870% of the company's total share capital, between September 1 and September 12, 2025 [1] - The reduction was executed at a price range of 51.75 to 65.54 yuan per share, totaling 75.8397 million yuan [1] - Following the completion of this reduction plan, Xu Xiaoqiang currently holds 674,800 shares, which is 0.5139% of the total shares, while Xu Yan's holdings of 18.48 million shares remain unchanged [1]

Group 1 - The chemical pharmaceutical sector increased by 0.78% on September 12, with Yuan Dong Biological leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] - Notable gainers in the chemical pharmaceutical sector included Yuan Dong Biological, which rose by 11.33% to a closing price of 58.88, and Nuo Cheng Jian Hua, which increased by 11.14% to 29.62 [1] Group 2 - The chemical pharmaceutical sector saw a net inflow of 628 million yuan from institutional investors, while retail investors experienced a net outflow of 776 million yuan [2][3] - Major stocks with significant net inflows included Guang Sheng Tang with 264 million yuan and An Li Kang with 130 million yuan [3] - Conversely, stocks like Tai En Kang and Xin Ju Wei faced declines of 3.89% and 2.41%, respectively, indicating mixed performance within the sector [2]

Group 1 - Warner Pharmaceuticals' stock rose by 1.43% to close at 56.13 yuan on September 10 [1] - A block trade occurred with a total volume of 115,900 shares and a transaction value of 5.472 million yuan, with a discount rate of -15.91% [1] - The buyer was Guotai Junan Securities Co., Ltd. Shenzhen branch, and the seller was GF Securities Co., Ltd. Shenyang Xiaoxilu Securities branch [1] Group 2 - Over the past three months, the stock has recorded one block trade with a total transaction value of 5.472 million yuan [1] - In the last five trading days, the stock has declined by 3.31%, while the net inflow of main funds totaled 20.0214 million yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，湖南华纳大药厂股份有限公司（以下简称 "公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司 联合举办的"资本聚三湘 楚光耀新程——2025 年湖南辖区上市公司投资者网上 集体接待日暨半年度业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参与 本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）14:00-17:00。 届时，公司管理层将在线就公司经营业绩、公司治理、发展战略等投资者所关 心的问题，与投资者进行深入交流，欢迎广大投资者踊跃参与！ 特此公告。 证券代码：688799 证券简称：华纳药厂 公告编号：2025-076 湖南华纳大药厂股份有限公司 关于参加2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 湖南华纳大药厂股份有限 ...

两融数据显示，该股最新融资余额为4.52亿元，近5日增加8116.80万元，增幅为21.92%。（数据宝） 9月10日华纳药厂大宗交易一览 华纳药厂9月10日大宗交易平台出现一笔成交，成交量11.59万股，成交金额547.20万元，大宗交易成交 价为47.20元，相对今日收盘价折价15.91%。该笔交易的买方营业部为国泰海通证券股份有限公司深圳 分公司，卖方营业部为广发证券股份有限公司沈阳小西路证券营业部。 证券时报·数据宝统计显示，华纳药厂今日收盘价为56.13元，上涨1.43%，日换手率为2.84%，成交额为 2.09亿元，全天主力资金净流出70.55万元，近5日该股累计下跌3.31%，近5日资金合计净流入4496.81万 元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 11.59 | 547.20 | 47.20 | -15.91 | 国泰海通证券股份有 | 广发证券股份有 ...

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, attributed to intense market competition and policy impacts, but is optimistic about future growth through specialized marketing teams and ongoing R&D efforts [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 714 million yuan, a year-on-year decrease of 3.37% [1]. - The net profit attributable to shareholders was 71 million yuan, down 36.95% year-on-year; excluding stock incentive expenses, the net profit was 90 million yuan, a decline of 19.89% [1]. - Revenue from raw material products was 180 million yuan, an increase of 2.13% year-on-year, while revenue from formulation products was 522 million yuan, a decrease of 5.93% [1]. Group 2: Marketing and Sales Strategy - The company established three specialized marketing teams: Raw and Auxiliary Materials Division, New Drug Division, and Formulation Marketing Center [1]. - The New Drug Division achieved sales of 67 million yuan, a year-on-year increase of 34.46%, while the Formulation Marketing Center's sales were 455 million yuan, down 10.08% [1]. Group 3: Research and Development - R&D investment in the first half of 2025 was 80 million yuan, a year-on-year increase of 20.94%, accounting for 11.26% of revenue, up 2.26 percentage points from the previous year [2]. - The company is advancing its clinical pipeline, with the Qianqing Granules in Phase III trials and ZG-001 in Phase IIa trials, showing promising safety results [2]. - ZG-001 is projected to reach peak sales of 3.56 billion yuan by 2032, with an estimated market penetration of 15.0% [2]. Group 4: Profit Forecast - The company forecasts revenues of 1.474 billion yuan, 1.593 billion yuan, and 1.742 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.30%, 8.07%, and 9.39% [3]. - The projected net profits for the same years are 141 million yuan, 170 million yuan, and 190 million yuan, with growth rates of -14.01%, 20.20%, and 11.83% [3]. - Corresponding EPS for these years are expected to be 1.08, 1.29, and 1.45 yuan, with PE ratios of 54.93, 45.70, and 40.87 times [3].

9月10日，华纳药厂大宗交易成交11.59万股，成交额547.2万元，占当日总成交额的2.55%，成交价47.2 元，较市场收盘价56.13元折价15.91%。 | 证券商除 华纳药厂 | 蓬券代码。 688799 | 成交价(元) 成交金额[万元] 成交量(*) 买入营业部 47.2 | 547.2 | 11.59 | 国泰海通证券股份 有限公司深圳分公 | 美出营业服 广发证券股份有限 公司沈阳小西路证 | 是否为专场 ea | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 025-09-10 | | | | | | | | ...

天眼查资料显示，华纳药厂成立于2001年04月30日，注册资本9380万人民币，法定代表人黄本东，注册 地址为湖南浏阳生物医药园区。主营业务为化学原料药、化学药制剂和中药制剂的研发、生产与销售。 目前，公司董事长为黄本东，董秘为乔桥，员工人数为1238人，实际控制人为黄本东。 雷达财经 文|冯秀语 编|李亦辉 9月7日，华纳药厂（证券代码：688799）发布公告称，其控股子公司上海致根医药科技有限公司通过增 资扩股引入战略投资者的事项已取得进展。根据公告，致根医药按照投前估值4亿元人民币获得了共计 6,999.8684万元的投资。此次增资事宜已经过公司董事会、监事会及股东大会审议通过，增资金额合计 不超过7,000万元。 目前，致根医药已完成工商变更登记，并取得了新的营业执照。 公司参股公司13家，包括湖南华纳大药厂手性药物有限公司、湖南华纳大药厂天然药物有限公司、湖南 华纳大药厂科技开发有限公司、湖南华纳大药厂医贸有限公司、湖南美和美诺生物技术有限公司等。 在业绩方面，公司2024年至2025(Q2)年营业收入分别为14.13亿元、3.36亿元和7.14亿元，同比分别增 长-1.38%、-9.83%和-3. ...